Goulart, H., Kantarjian, H., Jain, N., Khouri, R., Kadia, T., DiNardo, C., Daver, N., Pemmaraju, N., Ferrajoli, A., Bataller, A., Haddad, F., Senapati, J., Garcia-Manero, G., Garris, R., Ravandi, F., Short, N., Jabbour, E. (2025). The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study. Blood. https://doi.org/10.1182/blood-2025-1567